{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:42:36Z","timestamp":1648514556234},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1097\/mca.0000000000000624","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T20:40:05Z","timestamp":1523997605000},"page":"447-450","source":"Crossref","is-referenced-by-count":0,"title":["The ORBITA trial and the future of percutaneous coronary intervention for stable angina"],"prefix":"10.1097","volume":"29","author":[{"given":"Maayan","family":"Konigstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Ben-Yehuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210204","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-1-20210204","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-152-6-201003160-00007","article-title":"Meta-analysis: effects of percutaneous coronary intervention versus medical therapy on angina relief","volume":"152","author":"Wijeysundera","year":"2010","journal-title":"Ann Intern Med"},{"key":"R3-1-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM199201023260102","article-title":"A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators","volume":"326","author":"Parisi","year":"1992","journal-title":"N Engl J Med"},{"key":"R4-1-20210204","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/CIRCULATIONAHA.106.625475","article-title":"Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease","volume":"115","author":"Hueb","year":"2007","journal-title":"Circulation"},{"key":"R5-1-20210204","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jcin.2008.08.002","article-title":"Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study","volume":"1","author":"Nishigaki","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"R6-1-20210204","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R7-1-20210204","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force","year":"2013","journal-title":"Eur Heart J"},{"key":"R8-1-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial","volume":"391","author":"Al-Lamee","year":"2018","journal-title":"Lancet"},{"key":"R9-1-20210204","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"R10-1-20210204","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-1-20210204","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R12-1-20210204","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"R13-1-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R14-1-20210204","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/2047487312450133","article-title":"Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial","volume":"19","author":"Sendon","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"R15-1-20210204","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcin.2017.05.042","article-title":"in-hospital outcomes of percutaneous coronary intervention in America\u2019s Safety Net: insights from the NCDR Cath-PCI Registry","volume":"10","author":"Acharya","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R16-1-20210204","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.115.019768","article-title":"Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial","volume":"133","author":"Alexander","year":"2016","journal-title":"Circulation"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:49Z","timestamp":1620960169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201809000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000624","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}